What is VitriVax?
VitriVax is a biotechnology company dedicated to revolutionizing vaccine delivery and stability. At the core of its innovation is the ALTA® technology, which enables the development of thermostable, single-dose vaccines. This breakthrough addresses critical challenges in global health, particularly in regions with limited cold-chain infrastructure, thereby improving the reach and effectiveness of vital immunizations. The company's focus on accessibility and efficacy positions it as a key player in the next generation of vaccine development.
How much funding has VitriVax raised?
VitriVax has raised a total of $22.3M across 2 funding rounds:
Grant
$5M
Series B
$17.3M
Grant (2023): $5M with participation from Bill & Melinda Gates Foundation
Series B (2025): $17.3M led by Adjuvant Capital and RA Capital Management
Key Investors in VitriVax
Adjuvant Capital
Adjuvant Capital is a venture capital firm focused on financing innovative life science technologies that address high-burden public health challenges, particularly in infectious diseases and maternal health, aiming for both social and financial returns.
RA Capital Management
RA Capital Management is a multi-stage investment manager specializing in public and private healthcare and life science companies, with a focus on drug development, medical devices, and diagnostics, utilizing data-driven analysis to support their investment strategies.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is dedicated to supporting individuals experiencing hunger and extreme poverty by enabling them to lead healthier lives, with a focus on global health initiatives and innovative medical solutions.
What's next for VitriVax?
With the infusion of $17.3M in its latest strategic investment and a cumulative backing of $22.3M, VitriVax is poised for significant expansion. This capital injection is anticipated to fuel further research and development, scale manufacturing capabilities, and broaden the clinical application of its thermostable vaccine technology. The company's trajectory suggests a move towards commercialization and wider global deployment, aiming to solidify its position as a leader in accessible and stable vaccine solutions. Future growth will likely involve strategic partnerships and expanded clinical trials to validate and implement its innovative ALTA® platform across diverse public health initiatives.
See full VitriVax company page
